drugset / Trial / NCT05757219
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
Phase 2
Recruiting
27 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to assess the safety and efficacy of once daily itacitinib oral administration in participants with diffuse large B-cell lymphoma (DLBCL) who will receive CAR-T cell therapy with axicabtagene ciloleucel (axi-cel).
Timeline
- Start
- 2023-05-19
- Primary completion
- 2027-02
- Completion
- 2027-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Itacitinib | Small molecule | 200 mg | Oral |
| Background | Axicabtagene Ciloleucel | Cell therapy | — | — |